Envista Holdings Corp

Envista Holdings Corp(NVST)股票分析

$22.610

-0.287 (-1.27%)收盘时

Loading chart…
最高
23.045
开盘
22.940
成交量加权均价
22.74
成交量
2.54M
市值
2.83B
最低
22.565
成交额
57.78M
企业价值/息税折旧摊销前利润(TTM)
8.94

Envista Holdings Corporation provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, as well as to improve the aesthetics of the human smile. The Company is a provider of a range of solutions to support dental implants, orthodontic treatments, dental diagnostics, general dental consumable products, equipment and services. Its segments include Specialty Products & Technologies and Equipment & Consumables. The Specialty Products & Technologies segment primarily develops, manufactures and markets dental implant systems, including regenerative solutions, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, lab products, and loupes. The Equipment & Consumables segment develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems.

AI 分析 of Envista Holdings Corp (NVST)

持有

Currently, Envista Holdings Corp (NVST) is priced at $22.90, which is below the analyst consensus target of $31.32, indicating potential upside. However, the RSI is at 43.78, suggesting it is nearing oversold territory, and the forward P/E ratio is 16.81, which is reasonable compared to the sector. The main risk is the recent downgrades from Piper Sandler and BMO Capital, both lowering their price targets to $26, which could indicate potential headwinds in the near term.

估值指标

Envista Holdings Corp(NVST)当前预期市盈率为 16.81,5 年平均预期市盈率为 19.81。

预期市盈率

合理
5 年均值 P/E
19.81
当前P/E
16.81
高估
23.70
低估
15.91

预期 EV/EBITDA

低估
5 年均值 EV/EBITDA
12.21
当前EV/EBITDA
8.94
高估
14.34
低估
10.08

预期市销率

合理
5 年均值 P/S
1.75
当前P/S
1.23
高估
2.30
低估
1.20

Alphio AI 对 NVST 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%NVST

$18.76

情景价格

基

基准

基准 · 50%NVST

$17.69

情景价格

悲

悲观

悲观 · 25%NVST

$15.35

情景价格

持有 NVST 的大户

I

Ilex Capital Partners (Uk) LLP

+ 持有NVST

+1.53%

3个月收益率

T

Tweedy, Browne Company LLC

+ 持有NVST

-0.83%

3个月收益率

P

Paradice Investment Management Pty Ltd.

+ 持有NVST

-3.69%

3个月收益率

A

Ariel Investments, LLC

+ 持有NVST

-4.04%

3个月收益率

D

Deerfield Management Company, L.P.

+ 持有NVST

-8.65%

3个月收益率

G

Gates Capital Management, Inc.

+ 持有NVST

-9.48%

3个月收益率

事件时间线

2026-10-15 (ET)

08:30:00

Kerr Dental Launches ZenFlex RT Rotary Retreatment Files

2026-09-03 (ET)

16:30:00

Major Averages Close Sharply Higher, Nasdaq Up 1.40%

12:00:00

Major Averages Surge at Noon, Nasdaq Up 1.34%

2026-08-05 (ET)

16:30:00

Company Reports Q2 Revenue of $731M, Exceeds Expectations

16:30:00

Raises 2026 Revenue Growth Outlook to 3.5%-4.5%

资讯

NVST 常见问题 —— 由 Alphio AI 解答

Envista Holdings Corporation provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, as well as to improve the aesthetics of the human smile. The Company is a provider of a range of solutions to support dental implants, orthodontic treatments, dental diagnostics, general dental consumable products, equipment and services. Its segments include Specialty Products & Technologies and Equipment & Consumables. The Specialty Products & Technologies segment primarily develops, manufactures and markets dental implant systems, including regenerative solutions, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, lab products, and loupes. The Equipment & Consumables segment develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems. It operates in the Healthcare sector (DENTAL EQUIPMENT & SUPPLIES industry).

Currently, Envista Holdings Corp (NVST) is priced at $22.90, which is below the analyst consensus target of $31.32, indicating potential upside. However, the RSI is at 43.78, suggesting it is nearing oversold territory, and the forward P/E ratio is 16.81, which is reasonable compared to the sector. The main risk is the recent downgrades from Piper Sandler and BMO Capital, both lowering their price targets to $26, which could indicate potential headwinds in the near term.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易